Psammaplin A is a natural prodrug that inhibits class I histone deacetylase

Experimental and Molecular Medicine

Volumn 39, Issue 1, 2007, Pages 47-55

  Dong, Hoon Kim ^a   Shin, Jongheon ^b   Ho, Jeong Kwon ^a  

^a Yonsei University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Antineoplastic agents; Histone deacetylases; Prodrugs; Psammaplin A

Indexed keywords

GELSOLIN; GLUTATHIONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; PSAMMAPLIN A; PSAMMAPLIN B; PSAMMAPLIN E; PSAMMAPLIN F; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MARINE SPECIES; SPONGE (PORIFERA); UPREGULATION;

EID: 33847657556     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Batova A., Shao LE, Diccianni MB, Yu AL, Tanaka T, Rephaeli A, Nudelman A, Yu J. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 2002;100:3319-24
2. Davie JR. Covalent modification of histones: expression from chromatin templates. Curr Opin Genet Dev 1998;8:173-8
3. Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert JP, Evans RM, Albagli O. The LAZ3 (BCL06) oncoprotein recruits a SMRT/Msin3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 1998;26:4645-51
4. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-93
5. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62:4916-21
6. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci 2003;100:4389-94
7. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan, JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003;100:2041-46
8. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 1994;214:189-97
9. Hur JM, Shim JS, Jung HJ, Kwon HJ. Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Exp Mol Med 2005;37:133-7
10. Jung JH, Sim CJ, Lee CO. Cytotoxic compounds from a two-sponge association. J Nat Prod 1995;58:1722-6
11. Kam CM, Nishino N, Powers JC. Inhibition of thermolysin and carboxypeptidase A by phosphoramidates. Biochemistry 1979;18:3032-38
12. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43
13. Kato H, Tamamizu-Kato S. Shibasaki F. Histone deacetylase 7 associates with hypoxia-inducible factor-1 and increases transcriptional activity. J Biol Chem 2004; 279:41966-74
14. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9:3578-88
15. Kim D, Lee IS, Jung JH, Lee CO, Choi SU. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells. Anticancer Res 1999;19:4085-90
16. Kim DH, Kim MJ, Kwon HJ. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 2003;36:110-9
17. Kim DH, Shim JS, Kwon HJ. Coordinated transcriptional regulation of calmegin, a testis-specific molecular chaperon, by histone deacetylase and CpG methyltransferase. Exp Mol Med 2005;37:492-6.
18. Kim JH, Shim JS, Lee SK, Kim KW, Rha SY, Chung HC, Kwon HJ. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Jpn J Cancer Res 2002;93:1378-85
19. Kim MS, Kwon HJ, Lee YM, Baec JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim GW. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-43
20. Lander J, Sutton A, Tafrov ST, Heller RC, Stebbin J, Pillus L, Sternglanz R. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylase. Proc Natl Acad Sci USA 2000;97:5807-11
21. Marks PA, Rifkind RA. Erythroleukemic differentiation. Annu Rev Biochem 1978;47:419-48
22. Nicholas GM, Eckman LL, Ray S, Hughes RO, Pfefferkorn JA, Barluenga S, Nicolaou KC, Bewley CA. Bromotyrosine-derived natural and synthetic products as inhibitors of mycothiol-S-conjugate amidase. Bioorg Med Chem Lett 2003;12:2487-90
23. Nishino N, Powers JC. Design of potent reversible inhibitors for thermolysin. Peptides containing zinc coordinating ligands and their use in affinity chromatography. Biochemistry 1978;18:4340-47
24. Nishino N, Jose B, Okamura S, Ebisusaki S, Kato T, Sumida Y, Yoshida M. Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. Org Lett 2003;5:5079-82
25. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977;196:441-4
26. Pandolfi PP. Transcription therapy for cancer. Oncogene 2001;20:3116-27
27. Park Y, Liu Y, Hong J, Lee CO, Cho H, Kim DK, Im KS, Jung JH. New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis. J Nat Prod 2003;66:1495-8
28. Paroni G, Mizzau M, Henderson C, Del Sal G, Shineider C, Brancolini C. Caspase-dependent regulation of histone deacetylase 4 nuclear-cytoplasmic shuttling promotes apoptosis. Mol Biol Cell 2004;15:2804-18
29. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-8
30. Pina IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perez LB, Bair KW, Crews P. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 2003;68:3866-73
31. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996;93:5705-8
32. Saito A, Yanashita T, Mariki Y, Nosaka Y, Tsuchiya K, Ando T. A synthetic inhibitor of histone deaceylase, MS-27-275, with marked in vivo antitumor activity against human tumor. Proc Natl Acad Sci USA 1999; 96:4592-97
33. Shim JS, Lee HS, Shin J, and Kwon HJ. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett 2004; 203:63-9
34. Shrieve DC, Denekamp J, Minchinton AI. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro. Radiat Res 1985;102:283-94
35. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Expr 1996;5:245-54
36. Vanhaecke T, Papeleu P, Elaut G, Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 2004;11:1629-43
37. Xiao JJ, Byrd J, Marcucci G, Grever M, Chan KK. Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Commun Mass Spectrom 2003:17:757-66
38. Yurek-George A, Habens F, Brimmell M, Packham G, Ganesan A. Total synthesis of spiruchostatin A, a potent histone deacetylase inhibitor. J Am Chem Soc 2004;126:1030-1